Barcelona-based Gate2Brain secures €7 million to advance brain tumour candidate

Gate2Brain, a Spanish BioTech company developing a therapeutic candidate for aggressive paediatric  and adult brain tumours, has announced a €7 million investment – the largest investment raised by the company to date. The investment represent a 30.4% equity stake and strategic partnership with Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited. “Gate2Brain acknowledges the continued support of its institutional partners, external advisors, investors and business angels, whose confidence and commitment have played a key role in advancing the company’s mission and technology platform,” says Dr. Meritxell Teixidó, Gate2Brain CEO & CSO. Gate2Brain’s investment sits within a 2026 EU-Startups funding landscape in which European BioTech capital has continued to flow into oncology, CNS-related delivery, RNA-based therapeutics, protein degradation and clinical-trial infrastructure. The round is smaller than later-stage or platform rounds such as STORM Therapeutics’ €47.5 million Series C and Aerska’s €32 million Series A, but is broadly comparable with earlier-stage therapeutic platform financings such as iDEL Therapeutics’ €9 million Seed and Kupando’s €10 million additional Series A. The presence of Barcelona-based Biorce in adjacent Spanish HealthTech activity also points to domestic activity around clinical development infrastructure, although Gate2Brain’s focus remains more narrowly therapeutic, particularly blood-brain barrier delivery for brain tumours and CNS diseases. Founded in 2020, as a spin-off from IRB Barcelona, the University of Barcelona and Hospital Sant Joan de Déu Barcelona, Gate2Brain is advancing its proprietary technology platform to address high unmet medical needs in paediatric and adult brain tumours, as well as other central nervous system diseases. Gate2Brain has received support from leading public and private institutions, including Fundación Botín (Mind the Gap), Banco Sabadell (BStartup Health), CDTI Innovación, the European Innovation Council (EIC Accelerator), ACCIÓ Startup Capital, and Fundación ”la Caixa”. A key focus of the partnership is G2B-002, Gate2Brain’s lead candidate. G2B-002 uses Gate2Brain’s proprietary MiniAp4 peptide shuttle to address one of the major challenges in central nervous system diseases: enabling therapeutics to cross the blood-brain barrier. Preclinical studies have reportedly demonstrated improved brain delivery and reduced side effects in paediatric brain tumours. By combining Gate2Brain’s technology with Shilpa’s expertise in manufacturing, CMC development and regulatory strategy, the partnership aims to accelerate the development of G2B-002 while supporting the expansion of the company’s technology platform into additional therapeutic areas and CNS applications. This collaboration marks an important step in advancing G2B-002 from preclinical development toward clinical application, while reinforcing Gate2Brain’s mission to address critical unmet medical needs in paediatric brain cancer and other central nervous system diseases, increasing the potential to deliver therapies to children and families facing devastating brain tumours. The post Barcelona-based Gate2Brain secures €7 million to advance brain tumour candidate appeared first on EU-Startups.